Patents by Inventor Jamie Harue HIRATA

Jamie Harue HIRATA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES TO TREAT DIFFUSE LARGE B-CELL LYMPHOMA
    Publication number: 20240115718
    Abstract: Provided herein are methods of treating B-cell proliferative disorders (such as diffuse large B-cell lymphoma “DLBCL”) using immunoconjugates comprising anti-CD79b antibodies in combination with an immunomodulatory agent (such as lenalidomide) and an anti-CD20 antibody (such as obinutuzumab or rituximab).
    Type: Application
    Filed: November 9, 2023
    Publication date: April 11, 2024
    Applicant: Genentech, Inc.
    Inventors: Jamie Harue HIRATA, Lisa Linnea MUSICK
  • METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES
    Publication number: 20230270875
    Abstract: Provided herein are methods of treating B-cell proliferative disorders (such as Follicular Lymphoma and diffuse large B cell lymphoma) using immunoconjugates comprising anti-CD79b antibodies in combination with a Bcl-2 inhibitor (such as venetoclax) and an anti-CD20 antibody (such as obinutuzumab or rituximab).
    Type: Application
    Filed: October 24, 2022
    Publication date: August 31, 2023
    Applicant: Genentech, Inc.
    Inventors: Jamie Harue HIRATA, Lisa MUSICK
  • METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES TO TREAT DIFFUSE LARGE B-CELL LYMPHOMA
    Publication number: 20230099756
    Abstract: Provided herein are methods of treating B-cell proliferative disorders (such as diffuse large B-cell lymphoma “DLBCL”) using immunoconjugates comprising anti-CD79b antibodies in combination with an anti-CD20 antibody, chemotherapy and a corticosteroid.
    Type: Application
    Filed: August 5, 2022
    Publication date: March 30, 2023
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Jamie Harue HIRATA, Calvin Ka Yin Lee, Huan Jin, Lijia Wang, Jiaheng Qiu, Qingxiang Yan
  • METHODS OF USING ANTI-CD79b IMMUNOCONJUGATES TO TREAT FOLLICULAR LYMPHOMA
    Publication number: 20220125942
    Abstract: Provided herein are methods of treating B-cell proliferative disorders (such as Follicular Lymphoma “FL”) using immunoconjugates comprising anti-CD79b antibodies in combination with an immunomodulatory agent (such as lenalidomide) and an anti-CD20 antibody (such as obinutuzumab or rituximab).
    Type: Application
    Filed: November 12, 2021
    Publication date: April 28, 2022
    Applicant: Genentech, Inc.
    Inventors: Lisa MUSICK, Jamie Harue HIRATA
  • METHODS OF USING ANTI-CD79b IMMUNOCONJUGATES
    Publication number: 20220040153
    Abstract: Provided herein are methods of treating B-cell proliferative disorders in particular Follicular Lymphoma and/or Diffuse Large B-Cell Lymphoma using immunoconjugates comprising anti-CD79b antibodies in combination with additional therapeutic agents.
    Type: Application
    Filed: April 14, 2021
    Publication date: February 10, 2022
    Applicant: Genentech, Inc.
    Inventors: Andrew POLSON, Shang-Fan YU, Yu-Waye CHU, Michael WENGER, Jamie Harue HIRATA, Dan LU
  • COMBINATION THERAPY OF DIFFUSE LARGE B-CELL LYMPHOMA COMPRISING AN ANTI-CD79B IMMUNOCONJUGATES, AN ALKYLATING AGENT AND AN ANTI-CD20 ANTIBODY
    Publication number: 20220031861
    Abstract: Provided herein are methods of treating B-cell proliferative disorders (such as Diffuse Large B-Cell Lymphoma “DLBCL”) using immunoconjugates comprising anti-CD79b antibodies in combination with an alkylating agent (such as bendamustine) and an anti-CD20 antibody (such as rituximab).
    Type: Application
    Filed: June 3, 2021
    Publication date: February 3, 2022
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Jamie Harue HIRATA, Grace Hsiao-Wen KU, Ji CHENG
  • METHODS OF USING ANTI-CD79b IMMUNOCONJUGATES
    Publication number: 20210346352
    Abstract: Provided herein are methods of treating B-cell proliferative disorders in particular Follicular Lymphoma and/or Diffuse Large B-Cell Lymphoma using immunoconjugates comprising anti-CD79b antibodies in combination with additional therapeutic agents.
    Type: Application
    Filed: May 10, 2021
    Publication date: November 11, 2021
    Applicant: Genentech, Inc.
    Inventors: Andrew POLSON, Shang-Fan YU, Yu-Waye CHU, Michael WENGER, Jamie Harue HIRATA, Dan LU
  • Methods of using anti-CD79b immunoconjugates
    Patent number: 11000510
    Abstract: Provided herein are methods of treating B-cell proliferative disorders in particular Follicular Lymphoma and/or Diffuse Large B-Cell Lymphoma using immunoconjugates comprising anti-CD79b antibodies in combination with additional therapeutic agents.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: May 11, 2021
    Assignee: Genentech, Inc.
    Inventors: Andrew Polson, Shang-Fan Yu, Yu-Waye Chu, Michael Wenger, Jamie Harue Hirata, Dan Lu
  • METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES TO TREAT DIFFUSE LARGE B-CELL LYMPHOMA
    Publication number: 20210115141
    Abstract: Provided herein are methods of treating B-cell proliferative disorders (such as diffuse large B-cell lymphoma (DLBCL)) using immunoconjugates comprising anti-CD79b antibodies in combination with an anti-CD20 antibody (such as rituximab) and one or more chemotherapeutic agents (such as gemcitabine and oxaliplatin).
    Type: Application
    Filed: October 19, 2020
    Publication date: April 22, 2021
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Juana Elva HERNANDEZ MONTALVO, Naseer Ul Din QAYUM, Jamie Harue HIRATA